76 related articles for article (PubMed ID: 23405965)
1. Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Luo X; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Chem Biol Drug Des; 2013 Jun; 81(6):730-41. PubMed ID: 23405965
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Mol Divers; 2013 May; 17(2):221-43. PubMed ID: 23378232
[TBL] [Abstract][Full Text] [Related]
3. Viral infectivity factor: a novel therapeutic strategy to block HIV-1 replication.
Yang G; Xiong X
Mini Rev Med Chem; 2013 Jun; 13(7):1047-55. PubMed ID: 23621690
[TBL] [Abstract][Full Text] [Related]
4. 1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists.
Mohammed I; Kummetha IR; Singh G; Sharova N; Lichinchi G; Dang J; Stevenson M; Rana TM
J Med Chem; 2016 Aug; 59(16):7677-82. PubMed ID: 27509004
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors.
Pu C; Luo RH; Zhang M; Hou X; Yan G; Luo J; Zheng YT; Li R
Bioorg Med Chem Lett; 2017 Sep; 27(17):4150-4155. PubMed ID: 28754362
[TBL] [Abstract][Full Text] [Related]
6. Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
Zhong X; Luo R; Yan G; Ran K; Shan H; Yang J; Liu Y; Yu S; Pu C; Zheng Y; Li R
Eur J Med Chem; 2021 Nov; 224():113680. PubMed ID: 34245947
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.
Ali A; Wang J; Nathans RS; Cao H; Sharova N; Stevenson M; Rana TM
ChemMedChem; 2012 Jul; 7(7):1217-29. PubMed ID: 22555953
[TBL] [Abstract][Full Text] [Related]
8. Baculiferins A-O, O-sulfated pyrrole alkaloids with anti-HIV-1 activity, from the Chinese marine sponge Iotrochota baculifera.
Fan G; Li Z; Shen S; Zeng Y; Yang Y; Xu M; Bruhn T; Bruhn H; Morschhäuser J; Bringmann G; Lin W
Bioorg Med Chem; 2010 Aug; 18(15):5466-74. PubMed ID: 20624681
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.
Zhang RH; Wang S; Luo RH; Zhou M; Zhang H; Xu GB; Zhao YL; Li YJ; Wang YL; Yan G; Liao SG; Zheng YT; Li R
Bioorg Med Chem Lett; 2019 Dec; 29(24):126638. PubMed ID: 31685340
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line.
Shen YM; Lv PC; Chen W; Liu PG; Zhang MZ; Zhu HL
Eur J Med Chem; 2010 Jul; 45(7):3184-90. PubMed ID: 20304535
[TBL] [Abstract][Full Text] [Related]
11. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors.
He XY; Zou P; Qiu J; Hou L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2011 Nov; 19(22):6726-34. PubMed ID: 22014749
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription.
Carr JM; Coolen C; Davis AJ; Burrell CJ; Li P
Virology; 2008 Mar; 372(1):147-56. PubMed ID: 18037155
[TBL] [Abstract][Full Text] [Related]
14. Identification of benzenesulfonamide quinoline derivatives as potent HIV-1 replication inhibitors targeting Rev protein.
Zhong F; Geng G; Chen B; Pan T; Li Q; Zhang H; Bai C
Org Biomol Chem; 2015 Feb; 13(6):1792-9. PubMed ID: 25503645
[TBL] [Abstract][Full Text] [Related]
15. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
Adekale MA; Cane PA; McCrae MA
J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
[TBL] [Abstract][Full Text] [Related]
16. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor.
Sinha C; Nischal A; Bandaru S; Kasera P; Rajput A; Nayarisseri A; Khattri S
Curr Top Med Chem; 2015; 15(1):65-72. PubMed ID: 25579575
[TBL] [Abstract][Full Text] [Related]
17. Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays.
Hu G; Li X; Zhang X; Li Y; Ma L; Yang LM; Liu G; Li W; Huang J; Shen X; Hu L; Zheng YT; Tang Y
J Med Chem; 2012 Nov; 55(22):10108-17. PubMed ID: 23046280
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Zhan P; Chen W; Li Z; Li X; Chen X; Tian Y; Pannecouque C; Clercq ED; Liu X
Bioorg Med Chem; 2012 Dec; 20(23):6795-802. PubMed ID: 23098609
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents.
Mizuhara T; Oishi S; Ohno H; Shimura K; Matsuoka M; Fujii N
Bioorg Med Chem; 2012 Nov; 20(21):6434-41. PubMed ID: 23022280
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
Chen S; Chen R; He M; Pang R; Tan Z; Yang M
Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
